CepTor Announces New Compound Patents Pending for Neurodur in Multiple Sclerosis.HUNT VALLEY, Md. -- CepTor Corporation (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CEPO CEPO County Emergency Planning Officer (UK) CEPO Community & Environment Project Office (Edmonton Green, North London) ) today announced that intellectual property filings have been made to further strengthen its patent position for the Company's nerve cell nerve cell n. 1. See neuron. 2. The body of a neuron without its axon and dendrites. targeted protease inhibitor protease inhibitor (prō`tē-ās'), any of a class of drugs that interfere with replication of the AIDS virus (HIV), by blocking an enzyme (protease) necessary in the late stages of its reproduction. platform technology. More specifically, CepTor has filed to receive an additional 20 years of compound protection for oral delivery of Neurodur with accompanied use protection in multiple sclerosis (MS) and other neurodegenerative diseases. William Pursley, CepTor's Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. stated, "Protecting our property remains a never-ending priority. We are unaware of any other specific nerve cell targeted, protease protease /pro·te·ase/ (pro´te-as) endopeptidase. pro·te·ase n. Any of various enzymes, including the proteinases and peptidases, that catalyze the hydrolytic breakdown of proteins. inhibiting compounds being used or developed to minimize or prevent the degradation of nerve tissue associated with MS and other neurodegenerative diseases. We believe specific targeting provides us the unique benefit of potentially delivering our therapeutic compounds more safely and, in terms of efficacy, more efficiently." About CepTor Corporation CepTor Corporation is a biopharmaceutical company focusing on the development of proprietary, cell-targeted therapeutic products for neuromuscular and neurodegenerative diseases. The Company's mission is to increase the quality and quantity of life of people suffering with these diseases. CepTor's primary efforts are currently being focused on moving its lead product, MYODUR, into phase I/II clinical trials for Duchenne's muscular dystrophy Duchenne's muscular dystrophy, n an X-linked recessive condition pres-ent at birth in which the muscles of the pelvis and legs waste away in a symmetric fashion. . The Company's broad platform technology also includes the development of products for multiple sclerosis, retinal degeneration and epilepsy. This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. review process and other government regulation, our pharmaceutical collaborator's ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion